Advancements in Cancer Research: Genetic Testing and Early Detection

During Breast Cancer Awareness Month in October 2025, the American Cancer Society spotlighted Dr. Steven Katz, a professor at the University of Michigan, for his significant contributions to breast cancer research. Dr. Katz, funded by the American Cancer Society, leads the GIFT (Genetic Information and Family Testing) study, which aims to enhance access to genetic counseling and testing for breast cancer patients and their families. His research focuses on identifying hereditary cancer predispositions, such as BRCA1 and BRCA2 genes, and promoting home-based genetic testing for families. Dr. Katz emphasized the importance of genetic counseling, stating, “Our research underscores the urgent need to ensure all breast cancer survivors, regardless of background, have access to these services.”

Press ReleasesDr. Heather Parsons to lead Fred Hutch’s breast cancer initiativesBreast Cancer Deaths Drop 40% Since 1985 as Research Improves Treatment OptionsRed River Valley NewsFierce BiotechDiagnostics Are Making Personalized Care a RealityScience Daily

The American Cancer Society has invested over $100 million in breast cancer research, supporting initiatives that directly impact patient care and survivorship. Dr. Christina Annunziata, senior vice president at the American Cancer Society, noted that Dr. Katz's work exemplifies the organization's commitment to bridging research and patient experience.

Press ReleasesBreast Cancer Deaths Drop 40% Since 1985 as Research Improves Treatment OptionsDr. Heather Parsons to lead Fred Hutch’s breast cancer initiativesRed River Valley NewsScience DailyNew research identifies relapse risk in multiple myeloma patientsTechnology Networks

Research from The Institute of Cancer Research in London has revealed a more accurate method for predicting early relapse in multiple myeloma patients, a type of blood cancer. By combining traditional DNA profiling with RNA gene expression testing, the study found that 84% of early relapses could be predicted. This dual testing approach allows for more personalized treatment plans, potentially improving survival rates for the over 33,000 individuals affected by multiple myeloma in the UK.

Fierce BiotechNew research identifies relapse risk in multiple myeloma patientsTechnology NetworksDr. Heather Parsons to lead Fred Hutch’s breast cancer initiatives

Professor Martin Kaiser, who led the study, stated, “Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss.” The Royal Marsden hospital plans to implement the new gene expression profiling test, MMprofiler, in early 2026, enhancing diagnostic accuracy and treatment planning.

New research identifies relapse risk in multiple myeloma patients

Liquid biopsies, which analyze circulating tumor DNA (ctDNA) in blood samples, are emerging as a transformative tool in cancer detection and monitoring. Dr. Heather Parsons from Fred Hutch is developing ctDNA tests that can identify cancer characteristics and guide personalized treatment. This method allows for non-invasive monitoring of tumor dynamics over time, offering a promising alternative to traditional biopsies.

Dr. Heather Parsons to lead Fred Hutch’s breast cancer initiativesDiagnostics Are Making Personalized Care a RealitySignals of Change: How Biomarkers Are Reshaping Oncology and Healthcare DeliveryScience DailyNew research identifies relapse risk in multiple myeloma patientsFierce Biotech

Dr. Parsons highlighted the potential of ctDNA testing to revolutionize cancer care, stating, “We might be able to guide therapy based on the results of the liquid biopsy.” This approach could lead to earlier interventions and more tailored therapies for patients.

Dr. Heather Parsons to lead Fred Hutch’s breast cancer initiatives

The advancements in genetic testing and early detection underscore a significant shift towards personalized medicine in oncology. As researchers continue to explore innovative diagnostic methods, the integration of genetic insights into treatment plans is expected to enhance patient outcomes and optimize healthcare resources. The ongoing commitment to funding and supporting cancer research remains crucial in the fight against this pervasive disease.

Diagnostics Are Making Personalized Care a Reality

• “The American Cancer Society’s mission-driven approach, focusing on outcomes as well as impact on patients and their families, has allowed our team to transform how breast cancer patients and survivors navigate treatment and survivorship,” — Dr. Steven Katz, University of Michigan

Press Releases

• “Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss.” — Professor Martin Kaiser, The Institute of Cancer Research

Technology Networks

The ongoing research efforts led by experts like Dr. Katz, Professor Kaiser, and Dr. Parsons highlight the critical advancements in cancer diagnostics and treatment. These innovations not only promise to improve patient care but also pave the way for a future where cancer can be detected and treated more effectively.

Press Releases